Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05851378 · ClinicalTrials.gov registry record · Early Phase 1
Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma
A Early Phase 1 study of Adult Gliomas, Mixed, sponsored by Robert Bok, MD, PhD.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05851378: Recruiting Early Phase 1 study of Adult Gliomas, Mixed, sponsored by Robert Bok, MD, PhD.
NCT05851378 is a Early Phase 1 study of Adult Gliomas, Mixed that is actively recruiting participants, run by Robert Bok, MD, PhD. The registered enrollment target is 40 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (25% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05851378, a Early Phase 1 study of Adult Gliomas, Mixed, is actively recruiting participants, sponsored by Robert Bok, MD, PhD.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in participants with isocitrate dehydrogenase (IDH) mutant glioma.
Primary Outcome
Signal-to-noise ratio (SNR) of HP 13C-aKG will be calculated voxel-by-voxel, and within each region of interest (ROI). The parameters considered will be the mean SNR, within these ROIs. Acquisition parameters will be optimized (such as spatial resolution) to have the highest metabolite SNR and metabolite contrast.
Conditions Studied
Interventions
- DRUG Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
- PROCEDURE Magnetic Resonance Image (MRI)
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-04-11 |
| Est. Completion | 2027-04-30 |
| Phase | Early Phase 1 |
What NCT05851378 shows while recruiting
NCT05851378 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (25% lower).
The record links to 1 condition, with Adult Gliomas, Mixed appearing as the primary indexed condition, and to 2 interventions - of which Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG) is the first listed.
NCT05851378 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05851378 about?
NCT05851378 is a clinical study titled "Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma". This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in participants with isocitrate dehydrogenase (IDH) mutant glioma.
What is the current status of trial NCT05851378?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 40 participants. The study started on 2023-04-11. Estimated completion is 2027-04-30.
What conditions does trial NCT05851378 study?
This clinical trial studies the following conditions: Adult Gliomas, Mixed.
What interventions are being tested in trial NCT05851378?
The interventions under investigation include: Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG) (DRUG), Magnetic Resonance Image (MRI) (PROCEDURE).
Who is sponsoring clinical trial NCT05851378?
This trial is sponsored by Robert Bok, MD, PhD, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05851378 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05851378's enrollment target sits among peer trials
40 629th of 2000 higher than 1,313 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI